Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma

•We evaluated the cost-effectiveness of anti-BCMA CAR-T therapy for heavily pretreated relapsed and refractory multiple myeloma patients was assessed using a Markov model incorporating various uncertainties.•The parameter that most significantly impacted cost-effectiveness was the assumption for long-term PFS with CAR-T.•Although anti-BCMA CAR-T is associated with extremely high costs at the start, it has the potential to be cost-effective under the optimistic PFS assumption.